Clinical Hematology International

Volume 2, Issue 3, September 2020
Review Article

1. Cold Agglutinin Disease

Amy P. Gabbard, Garrett S. Booth
Pages: 95 - 100
Cold agglutinin disease (CAD) is an uncommon form of cold autoimmune hemolytic anemia (AIHA). It should be considered in the differential diagnosis of elderly patients with unexplained chronic anemia presenting with or without cold-induced symptoms in the extremities, such as the fingers, ears, and nose....
Review Article

2. Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Uttam K. Rao, Brian G. Engelhardt
Pages: 101 - 108
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is...
Research Article

3. Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors

Natasha A. Jain, Marcus Y. Chen, Sujata Shanbhag, Prathima Anandi, Xin Tian, Sawa Ito, Priyanka A. Pophali, Kimberly Doucette, Robert Q. Le, Upneet Chawla, Eleftheria Koklanaris, Richard W. Childs, A. John Barrett, Minoo Battiwalla
Pages: 109 - 116
Long-term allogeneic hematopoietic cell transplant (allo-HCT) survivors suffer an elevated risk of coronary heart disease (CHD). We conducted a prospective, nonrandomized, cross-sectional study to screen asymptomatic survivors at a single allo-HCT center using cardiac computed tomography (CT) involving...
Research Article

4. Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C. Spaulding, Sue Visscher, Han W. Tun, Sikander Ailawadhi, Prakash Vishnu
Pages: 117 - 124
Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cycophosphamide,...
Correspondence

5. B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Meghali Goswami, Katherine E. Lindblad, Rahul Ramraj, Pradeep K. Dagur, Julie Thompson, J. Philip McCoy, Christopher S. Hourigan
Pages: 125 - 128
Correspondence

6. Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation

Federica Ricci, Serena Balducci, Francesca Guerrini, Susanna Grassi, Elena Ciabatti, Claudia Baratè, Maria Immacolata Ferreri, Cecilia Giuliani, Angelo Valetto, Mario Petrini, Sara Galimberti
Pages: 129 - 131